TQJ230 for Cardiovascular Disease
This trial will help to show if the drug reduces the risk of cardiovascular disease in patients who have already had a heart attack or stroke and who have high levels of Lp(a).
- Cardiovascular Disease and High Lp(a)
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Is this study popular in Canada?
"There are 100 sites currently enrolling patients for this trial, with locations in Murray, Milwaukee, Kalamazoo, and 100 other cities. If you enroll in the trial, try to select a location near you to minimize travel requirements."
Has TQJ230 received government sanctioning for public use?
"TQJ230 is a Phase 3 trial medication, which means that while there is some data suggesting its efficacy, there is also extensive data supporting its safety. Our team at Power gives it a score of 3."
Are researchers still signing up participants for this clinical trial?
"No, this study is not currently recruiting patients. While the trial was originally posted on December 12th, 2019, the most recent update was on October 7th, 2022. There are 430 other studies actively recruiting patients at this time."
Are the individuals taking part in this trial above the age of majority?
"In order to take part in this particular clinical trial, patients must be aged between 18 and 80 years old. If a patient falls outside of this age range, there are other options; 28 trials for those under 18 and 384 for seniors."
Could I potentially qualify to take part in this medical research?
"Those with lipoproteins and between the ages of 18-80 are eligible to participate in this trial. A total of 8324 individuals can join."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Novartis Investigative Site: < 48 hours
Average response time
- < 2 Days